Global Hypermetropia Treatment Market

Hypermetropia Treatment Comprehensive Study by Type (Prescription, Surgery), End-User (Hospitals, Specialty Centres, Diagnostic Centres, Clinics, Others), Laser Procedure Types (Photorefractive Keratectomy (PRK), Laser-Assisted in Situ Keratomileusis (LASIK), Laser Epithelial Keratomileusis (LASEK), Epi-LASIK & Laser Thermal Keratoplasty (LTK)) Players and Region - Global Market Outlook to 2030

Hypermetropia Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hypermetropia Treatment
Hypermetropia (hyperopia or farsightedness or long-sightedness) is a form of refractive error, whereby parallel rays of sunshine coming from the time are targeted behind the light-sensitive layer of the membrane once the attention is a must. hyperopia is a common general vision condition in adults. folks with hypermetropia should squint to see solely near objects. Reading, writing, laptop work, or drawing for a longer duration of your time could cause headache & eye strain. The hypermetropia treatment market may be segmented based on type, end-user, and region. supported type, the market may be classified as prescription lenses and surgery. The prescription lenses can be further sub-segmented into corrective lenses & eyeglasses. The surgery segment can be additional split into laser procedures, IOL implantation & nonlaser procedures. The laser procedures sub-segment can be classified into Photorefractive keratectomy (PRK), Laser-assisted in situ keratomileuses (LASIK), laser epithelial keratomileusis (LASEK), Epi-LASIK & optical device thermal keratoplasty (LTK). in addition, the IOL implantation sub-segment may be divided into Ahakia correction, Refractive lens exchange (RLE) & Phakic IOL. whereas the non-laser procedures sub-segment may be further segregated into conductive keratoplasty (CK), automatic lamellar keratoplasty (ALK) & Keratophakia, and Epi-keratophakia. based on end-user, the market can be split into hospitals, specialty centers, diagnostic centers, clinics & others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hypermetropia Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allergan plc (United States), Abbott Laboratories Inc. (United States), ALCON VISION LLC (Switzerland), Bausch & Lomb Incorporated (United States), Carl Zeiss Inc. (Germany), Essilor Ltd. (France), Haag-Streit (United Kingdom), Johnson & Johnson Vision (United States), Lasersight Technologies Inc. (United States), ORASIS Pharmaceuticals Ltd. (Israel), Topcon Corporation (Japan) and Visioneering Technologies, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Ziemer Ophthalmic Systems AG (Switzerland) and Zeiss International (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Hypermetropia Treatment market by Type (Prescription and Surgery) and Region.



On the basis of geography, the market of Hypermetropia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Hypermetropia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Laser Procedure Types, the sub-segment i.e. Photorefractive Keratectomy (PRK) will boost the Hypermetropia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase in Spending on Healthcare Costs and Increasing Recommendation from The Doctors for The Treatment

Market Growth Drivers:
Increasing Incidences of Vision Loss, High Prevalence of Hypermetropia and The Rise in Geriatric Population

Challenges:
Lack of Skilled Professional and Presence of Alternatives

Restraints:
High Cost of The Treatment

Opportunities:
Increasing Research in The Healthcare Field

Market Leaders and their expansionary development strategies
In October 2021, Allergan, a subsidiary of AbbVie, received approval from the Food and Drug Administration for Vuity (pilocarpine hydrochloric acid ophthalmic solution) 1.25% for the treatment of presbyopia, also known as age-related blurry near vision, in adults.
In May 2021, Johnson & Johnson Vision received the US FDA's approval for the ACUVUE Abiliti Overnight Therapeutic Lenses designed to reshape the cornea curve and help treat myopia progression in children.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Hypermetropia Treatment, Venture Capitalists and Private Equity Firms and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Prescription
  • Surgery
By End-User
  • Hospitals
  • Specialty Centres
  • Diagnostic Centres
  • Clinics
  • Others

By Laser Procedure Types
  • Photorefractive Keratectomy (PRK)
  • Laser-Assisted in Situ Keratomileusis (LASIK)
  • Laser Epithelial Keratomileusis (LASEK)
  • Epi-LASIK & Laser Thermal Keratoplasty (LTK)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Vision Loss
      • 3.2.2. High Prevalence of Hypermetropia
      • 3.2.3. The Rise in Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professional
      • 3.3.2. Presence of Alternatives
    • 3.4. Market Trends
      • 3.4.1. Increase in Spending on Healthcare Costs
      • 3.4.2. Increasing Recommendation from The Doctors for The Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hypermetropia Treatment, by Type, End-User, Laser Procedure Types and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hypermetropia Treatment (Value)
      • 5.2.1. Global Hypermetropia Treatment by: Type (Value)
        • 5.2.1.1. Prescription
        • 5.2.1.2. Surgery
      • 5.2.2. Global Hypermetropia Treatment by: End-User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Centres
        • 5.2.2.3. Diagnostic Centres
        • 5.2.2.4. Clinics
        • 5.2.2.5. Others
      • 5.2.3. Global Hypermetropia Treatment by: Laser Procedure Types (Value)
        • 5.2.3.1. Photorefractive Keratectomy (PRK)
        • 5.2.3.2. Laser-Assisted in Situ Keratomileusis (LASIK)
        • 5.2.3.3. Laser Epithelial Keratomileusis (LASEK)
        • 5.2.3.4. Epi-LASIK & Laser Thermal Keratoplasty (LTK)
      • 5.2.4. Global Hypermetropia Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Hypermetropia Treatment (Price)
      • 5.3.1. Global Hypermetropia Treatment by: Type (Price)
  • 6. Hypermetropia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan plc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ALCON VISION LLC (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch & Lomb Incorporated (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Carl Zeiss Inc. (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Essilor Ltd. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Haag-Streit (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson Vision (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lasersight Technologies Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. ORASIS Pharmaceuticals Ltd. (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Topcon Corporation (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Visioneering Technologies, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Hypermetropia Treatment Sale, by Type, End-User, Laser Procedure Types and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hypermetropia Treatment (Value)
      • 7.2.1. Global Hypermetropia Treatment by: Type (Value)
        • 7.2.1.1. Prescription
        • 7.2.1.2. Surgery
      • 7.2.2. Global Hypermetropia Treatment by: End-User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Centres
        • 7.2.2.3. Diagnostic Centres
        • 7.2.2.4. Clinics
        • 7.2.2.5. Others
      • 7.2.3. Global Hypermetropia Treatment by: Laser Procedure Types (Value)
        • 7.2.3.1. Photorefractive Keratectomy (PRK)
        • 7.2.3.2. Laser-Assisted in Situ Keratomileusis (LASIK)
        • 7.2.3.3. Laser Epithelial Keratomileusis (LASEK)
        • 7.2.3.4. Epi-LASIK & Laser Thermal Keratoplasty (LTK)
      • 7.2.4. Global Hypermetropia Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Hypermetropia Treatment (Price)
      • 7.3.1. Global Hypermetropia Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hypermetropia Treatment: by Type(USD Million)
  • Table 2. Hypermetropia Treatment Prescription , by Region USD Million (2018-2023)
  • Table 3. Hypermetropia Treatment Surgery , by Region USD Million (2018-2023)
  • Table 4. Hypermetropia Treatment: by End-User(USD Million)
  • Table 5. Hypermetropia Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 6. Hypermetropia Treatment Specialty Centres , by Region USD Million (2018-2023)
  • Table 7. Hypermetropia Treatment Diagnostic Centres , by Region USD Million (2018-2023)
  • Table 8. Hypermetropia Treatment Clinics , by Region USD Million (2018-2023)
  • Table 9. Hypermetropia Treatment Others , by Region USD Million (2018-2023)
  • Table 10. Hypermetropia Treatment: by Laser Procedure Types(USD Million)
  • Table 11. Hypermetropia Treatment Photorefractive Keratectomy (PRK) , by Region USD Million (2018-2023)
  • Table 12. Hypermetropia Treatment Laser-Assisted in Situ Keratomileusis (LASIK) , by Region USD Million (2018-2023)
  • Table 13. Hypermetropia Treatment Laser Epithelial Keratomileusis (LASEK) , by Region USD Million (2018-2023)
  • Table 14. Hypermetropia Treatment Epi-LASIK & Laser Thermal Keratoplasty (LTK) , by Region USD Million (2018-2023)
  • Table 15. South America Hypermetropia Treatment, by Country USD Million (2018-2023)
  • Table 16. South America Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 17. South America Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 18. South America Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 19. Brazil Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 20. Brazil Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 21. Brazil Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 22. Argentina Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 23. Argentina Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 24. Argentina Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 25. Rest of South America Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 26. Rest of South America Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 27. Rest of South America Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 28. Asia Pacific Hypermetropia Treatment, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 30. Asia Pacific Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 31. Asia Pacific Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 32. China Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 33. China Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 34. China Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 35. Japan Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 36. Japan Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 37. Japan Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 38. India Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 39. India Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 40. India Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 41. South Korea Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 42. South Korea Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 43. South Korea Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 44. Taiwan Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 45. Taiwan Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 46. Taiwan Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 47. Australia Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 48. Australia Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 49. Australia Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 53. Europe Hypermetropia Treatment, by Country USD Million (2018-2023)
  • Table 54. Europe Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 55. Europe Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 56. Europe Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 57. Germany Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 58. Germany Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 59. Germany Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 60. France Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 61. France Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 62. France Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 63. Italy Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 64. Italy Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 65. Italy Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 66. United Kingdom Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 67. United Kingdom Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 68. United Kingdom Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 69. Netherlands Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 70. Netherlands Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 71. Netherlands Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 72. Rest of Europe Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 73. Rest of Europe Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 74. Rest of Europe Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 75. MEA Hypermetropia Treatment, by Country USD Million (2018-2023)
  • Table 76. MEA Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 77. MEA Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 78. MEA Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 79. Middle East Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 80. Middle East Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 81. Middle East Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 82. Africa Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 83. Africa Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 84. Africa Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 85. North America Hypermetropia Treatment, by Country USD Million (2018-2023)
  • Table 86. North America Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 87. North America Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 88. North America Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 89. United States Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 90. United States Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 91. United States Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 92. Canada Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 93. Canada Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 94. Canada Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 95. Mexico Hypermetropia Treatment, by Type USD Million (2018-2023)
  • Table 96. Mexico Hypermetropia Treatment, by End-User USD Million (2018-2023)
  • Table 97. Mexico Hypermetropia Treatment, by Laser Procedure Types USD Million (2018-2023)
  • Table 98. Hypermetropia Treatment: by Type(USD/Units)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Hypermetropia Treatment: by Type(USD Million)
  • Table 112. Hypermetropia Treatment Prescription , by Region USD Million (2025-2030)
  • Table 113. Hypermetropia Treatment Surgery , by Region USD Million (2025-2030)
  • Table 114. Hypermetropia Treatment: by End-User(USD Million)
  • Table 115. Hypermetropia Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 116. Hypermetropia Treatment Specialty Centres , by Region USD Million (2025-2030)
  • Table 117. Hypermetropia Treatment Diagnostic Centres , by Region USD Million (2025-2030)
  • Table 118. Hypermetropia Treatment Clinics , by Region USD Million (2025-2030)
  • Table 119. Hypermetropia Treatment Others , by Region USD Million (2025-2030)
  • Table 120. Hypermetropia Treatment: by Laser Procedure Types(USD Million)
  • Table 121. Hypermetropia Treatment Photorefractive Keratectomy (PRK) , by Region USD Million (2025-2030)
  • Table 122. Hypermetropia Treatment Laser-Assisted in Situ Keratomileusis (LASIK) , by Region USD Million (2025-2030)
  • Table 123. Hypermetropia Treatment Laser Epithelial Keratomileusis (LASEK) , by Region USD Million (2025-2030)
  • Table 124. Hypermetropia Treatment Epi-LASIK & Laser Thermal Keratoplasty (LTK) , by Region USD Million (2025-2030)
  • Table 125. South America Hypermetropia Treatment, by Country USD Million (2025-2030)
  • Table 126. South America Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 127. South America Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 128. South America Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 129. Brazil Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 130. Brazil Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 131. Brazil Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 132. Argentina Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 133. Argentina Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 134. Argentina Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 135. Rest of South America Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 136. Rest of South America Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 137. Rest of South America Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 138. Asia Pacific Hypermetropia Treatment, by Country USD Million (2025-2030)
  • Table 139. Asia Pacific Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 140. Asia Pacific Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 141. Asia Pacific Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 142. China Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 143. China Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 144. China Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 145. Japan Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 146. Japan Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 147. Japan Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 148. India Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 149. India Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 150. India Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 151. South Korea Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 152. South Korea Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 153. South Korea Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 154. Taiwan Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 155. Taiwan Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 156. Taiwan Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 157. Australia Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 158. Australia Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 159. Australia Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 163. Europe Hypermetropia Treatment, by Country USD Million (2025-2030)
  • Table 164. Europe Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 165. Europe Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 166. Europe Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 167. Germany Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 168. Germany Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 169. Germany Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 170. France Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 171. France Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 172. France Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 173. Italy Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 174. Italy Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 175. Italy Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 176. United Kingdom Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 177. United Kingdom Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 178. United Kingdom Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 179. Netherlands Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 180. Netherlands Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 181. Netherlands Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 182. Rest of Europe Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 183. Rest of Europe Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 184. Rest of Europe Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 185. MEA Hypermetropia Treatment, by Country USD Million (2025-2030)
  • Table 186. MEA Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 187. MEA Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 188. MEA Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 189. Middle East Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 190. Middle East Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 191. Middle East Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 192. Africa Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 193. Africa Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 194. Africa Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 195. North America Hypermetropia Treatment, by Country USD Million (2025-2030)
  • Table 196. North America Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 197. North America Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 198. North America Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 199. United States Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 200. United States Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 201. United States Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 202. Canada Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 203. Canada Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 204. Canada Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 205. Mexico Hypermetropia Treatment, by Type USD Million (2025-2030)
  • Table 206. Mexico Hypermetropia Treatment, by End-User USD Million (2025-2030)
  • Table 207. Mexico Hypermetropia Treatment, by Laser Procedure Types USD Million (2025-2030)
  • Table 208. Hypermetropia Treatment: by Type(USD/Units)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hypermetropia Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Hypermetropia Treatment: by End-User USD Million (2018-2023)
  • Figure 6. Global Hypermetropia Treatment: by Laser Procedure Types USD Million (2018-2023)
  • Figure 7. South America Hypermetropia Treatment Share (%), by Country
  • Figure 8. Asia Pacific Hypermetropia Treatment Share (%), by Country
  • Figure 9. Europe Hypermetropia Treatment Share (%), by Country
  • Figure 10. MEA Hypermetropia Treatment Share (%), by Country
  • Figure 11. North America Hypermetropia Treatment Share (%), by Country
  • Figure 12. Global Hypermetropia Treatment: by Type USD/Units (2018-2023)
  • Figure 13. Global Hypermetropia Treatment share by Players 2023 (%)
  • Figure 14. Global Hypermetropia Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Hypermetropia Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Allergan plc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Allergan plc (United States) Revenue: by Geography 2023
  • Figure 19. Abbott Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott Laboratories Inc. (United States) Revenue: by Geography 2023
  • Figure 21. ALCON VISION LLC (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. ALCON VISION LLC (Switzerland) Revenue: by Geography 2023
  • Figure 23. Bausch & Lomb Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bausch & Lomb Incorporated (United States) Revenue: by Geography 2023
  • Figure 25. Carl Zeiss Inc. (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Carl Zeiss Inc. (Germany) Revenue: by Geography 2023
  • Figure 27. Essilor Ltd. (France) Revenue, Net Income and Gross profit
  • Figure 28. Essilor Ltd. (France) Revenue: by Geography 2023
  • Figure 29. Haag-Streit (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Haag-Streit (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Johnson & Johnson Vision (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson Vision (United States) Revenue: by Geography 2023
  • Figure 33. Lasersight Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Lasersight Technologies Inc. (United States) Revenue: by Geography 2023
  • Figure 35. ORASIS Pharmaceuticals Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 36. ORASIS Pharmaceuticals Ltd. (Israel) Revenue: by Geography 2023
  • Figure 37. Topcon Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Topcon Corporation (Japan) Revenue: by Geography 2023
  • Figure 39. Visioneering Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Visioneering Technologies, Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Global Hypermetropia Treatment: by Type USD Million (2025-2030)
  • Figure 42. Global Hypermetropia Treatment: by End-User USD Million (2025-2030)
  • Figure 43. Global Hypermetropia Treatment: by Laser Procedure Types USD Million (2025-2030)
  • Figure 44. South America Hypermetropia Treatment Share (%), by Country
  • Figure 45. Asia Pacific Hypermetropia Treatment Share (%), by Country
  • Figure 46. Europe Hypermetropia Treatment Share (%), by Country
  • Figure 47. MEA Hypermetropia Treatment Share (%), by Country
  • Figure 48. North America Hypermetropia Treatment Share (%), by Country
  • Figure 49. Global Hypermetropia Treatment: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Allergan plc (United States)
  • Abbott Laboratories Inc. (United States)
  • ALCON VISION LLC (Switzerland)
  • Bausch & Lomb Incorporated (United States)
  • Carl Zeiss Inc. (Germany)
  • Essilor Ltd. (France)
  • Haag-Streit (United Kingdom)
  • Johnson & Johnson Vision (United States)
  • Lasersight Technologies Inc. (United States)
  • ORASIS Pharmaceuticals Ltd. (Israel)
  • Topcon Corporation (Japan)
  • Visioneering Technologies, Inc. (United States)
Additional players considered in the study are as follows:
Ziemer Ophthalmic Systems AG (Switzerland) , Zeiss International (Germany)
Select User Access Type

Key Highlights of Report


Jan 2024 215 Pages 68 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hypermetropia Treatment Market Quantitative research analysis
Global Hypermetropia Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allergan plc (United States), Abbott Laboratories Inc. (United States), ALCON VISION LLC (Switzerland), Bausch & Lomb Incorporated (United States), Carl Zeiss Inc. (Germany), Essilor Ltd. (France), Haag-Streit (United Kingdom), Johnson & Johnson Vision (United States), Lasersight Technologies Inc. (United States), ORASIS Pharmaceuticals Ltd. (Israel), Topcon Corporation (Japan) and Visioneering Technologies, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Spending on Healthcare Costs " is seen as one of major influencing trends for Hypermetropia Treatment Market during projected period 2023-2030.
The Hypermetropia Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hypermetropia Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Canine Leptospirosis Comprehensive Study by Drug (Doxycycline, Penicillin, Ampicillin, Pfizerpen), Route of Administration (Oral, Intravenous), Distribution Channel (Veterinary hospital pharmacies, V...
$ 3450
Graves Disease Comprehensive Study by Type (Anti-Thyroid Drugs, Lodine and Iodides, Radioactive Lodine, Lonic Inhibitors), Application (Hospital, Specialty Clinics), Distribution Channel (Hospital Di...
$ 3450
Dystrophic Epidermolysis Bullosa Treatment Comprehensive Study by Therapy (Gene therapy, Bone Marrow (Stem Cell) Transplantation, Protein Replacement Therapies, Cell-based Therapies), Treatment (Anti...
$ 3750
Cutaneous T-cell Lymphomas (CTCL) Comprehensive Study by Type (Mycosis Fungoides (MF), Sezary Syndrome (SS), Others), Treatment (Radiation Therapy, Chemotherapy, Immunotherapy, Targeted therapy, Othe...
$ 3500
Lichen Nitidus Treatment Comprehensive Study by Type (Corticosteroids, Retinoid, Antihistamines, Phototherapy), Route of Administration (Topical, Oral), Diagnosis (Electrocardiogram, Electrophysiolog...
$ 3450
Breast Cancer Diagnostics Comprehensive Study by Type (Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomo...
$ 3750